National Guideline Clearinghouse | Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy.

National Guideline Clearinghouse | Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy.

National Institute for Health and Care Excellence (NICE)

• Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy. Thisupdates a previously published guideline summary.

Guideline Title Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy. Bibliographic Source(s) National Institute for Health and Care Excellence (NICE). Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy. London (UK): National Institute for Health and Care Excellence (NICE); 2015 Dec 16. 65 p. (Technology appraisal guidance; no. 374).  Guideline Status This is the current release of the guideline. This guideline updates a previous version: National Institute for Clinical Excellence (NICE). Erlotinib for the treatment of non-small-cell-lung cancer. London (UK): National Institute for Health and Clinical Excellence (NICE); 2008 Nov. 26 p. (Technology appraisal; no. 87). This guideline meets NGC's 2013 (revised) inclusion criteria.